Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

[1]  W. Markesbery,et al.  Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. , 2010, Free radical biology & medicine.

[2]  D. Petersen,et al.  Molecular mechanisms of 4-hydroxy-2-nonenal and acrolein toxicity: nucleophilic targets and adduct formation. , 2009, Chemical research in toxicology.

[3]  Ulrich Seidl,et al.  The cerebellum in mild cognitive impairment and Alzheimer's disease - a structural MRI study. , 2008, Journal of psychiatric research.

[4]  W. Markesbery,et al.  Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. , 2008, Free radical biology & medicine.

[5]  W. Markesbery,et al.  Improved predictive model for pre-symptomatic mild cognitive impairment and Alzheimer's disease , 2008, Neurological research.

[6]  J. Morrow,et al.  Trans‐4‐hydroxy‐2‐hexenal is a neurotoxic product of docosahexaenoic (22:6; n‐3) acid oxidation , 2008, Journal of neurochemistry.

[7]  D. Butterfield,et al.  Redox proteomic identification of 4-Hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease , 2008, Neurobiology of Disease.

[8]  W. Markesbery,et al.  Aβ solubility and deposition during AD progression and in APP×PS-1 knock-in mice , 2007, Neurobiology of Disease.

[9]  S. Kish,et al.  Levels of 4-Hydroxynonenal and Malondialdehyde Are Increased in Brain of Human Chronic Users of Methamphetamine , 2006, Journal of Pharmacology and Experimental Therapeutics.

[10]  W. Markesbery,et al.  Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease , 2006, Neurobiology of Aging.

[11]  D. Allan Butterfield,et al.  Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis , 2006, Neurobiology of Aging.

[12]  Toshihiko Osawa,et al.  Formation of Nepsilon-(succinyl)lysine in vivo: a novel marker for docosahexaenoic acid-derived protein modification. , 2006, Journal of lipid research.

[13]  W. Markesbery,et al.  Decreased RNA, and Increased RNA Oxidation, in Ribosomes from Early Alzheimer’s Disease , 2006, Neurochemical Research.

[14]  D. Butterfield,et al.  Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment , 2006, Neuroscience Letters.

[15]  W. Markesbery,et al.  Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment , 2006, Journal of neurochemistry.

[16]  J. Morrow,et al.  Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment , 2005, Annals of neurology.

[17]  W. Markesbery,et al.  Ribosome Dysfunction Is an Early Event in Alzheimer's Disease , 2005, The Journal of Neuroscience.

[18]  N. Salem,et al.  Lead exposure and (n-3) fatty acid deficiency during rat neonatal development alter liver, plasma, and brain polyunsaturated fatty acid composition. , 2005, The Journal of nutrition.

[19]  G. Perry,et al.  Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. , 2005, Free radical biology & medicine.

[20]  D. Butterfield,et al.  Proteomic analysis of oxidatively modified proteins induced by the mitochondrial toxin 3-nitropropionic acid in human astrocytes expressing the HIV protein tat. , 2005, Brain research. Molecular brain research.

[21]  H. Chung,et al.  Induction of endothelial iNOS by 4-hydroxyhexenal through NF-κB activation , 2004 .

[22]  R. Maccioni,et al.  Oxidative stress promotes tau dephosphorylation in neuronal cells: the roles of cdk5 and PP1. , 2004, Free radical biology & medicine.

[23]  H. Chung,et al.  NF‐κB activation mechanism of 4‐hydroxyhexenal via NIK/IKK and p38 MAPK pathway , 2004 .

[24]  H. Chung,et al.  Induction of endothelial apoptosis by 4-hydroxyhexenal. , 2004, European journal of biochemistry.

[25]  D. Butterfield,et al.  4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease , 2004, Neuroscience Letters.

[26]  C. Lin,et al.  The Identification and Characterization of Oxidized RNAs in Alzheimer's Disease , 2003, The Journal of Neuroscience.

[27]  G. Perry,et al.  Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. , 2002, European journal of biochemistry.

[28]  D. Price,et al.  High Molecular Weight Neurofilament Proteins Are Physiological Substrates of Adduction by the Lipid Peroxidation Product Hydroxynonenal* , 2002, The Journal of Biological Chemistry.

[29]  N. Salem,et al.  Ethanol consumption alters electroretinograms and depletes neural tissues of docosahexaenoic acid in rhesus monkeys: nutritional consequences of a low n-3 fatty acid diet. , 2001, Alcoholism, clinical and experimental research.

[30]  L. T. McGrath,et al.  Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. , 2001, QJM : monthly journal of the Association of Physicians.

[31]  Hee-Yong Kim,et al.  Mechanisms of action of docosahexaenoic acid in the nervous system , 2001, Lipids.

[32]  A. Nunomura,et al.  Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[33]  W. Markesbery,et al.  Acrolein is increased in Alzheimer’s disease brain and is toxic to primary hippocampal cultures , 2001, Neurobiology of Aging.

[34]  G. Perry,et al.  Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4‐hydroxy‐2‐nonenal , 2000, FEBS letters.

[35]  W. Markesbery,et al.  Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. , 2000, Free radical biology & medicine.

[36]  Xiongwei Zhu,et al.  In Alzheimer's Disease, Heme Oxygenase Is Coincident with Alz50, an Epitope of τ Induced by 4‐Hydroxy‐2‐Nonenal Modification , 2000, Journal of neurochemistry.

[37]  J. Ashford,et al.  “Preclinical” AD revisited , 2000, Neurology.

[38]  E. Tangalos,et al.  Neuropathological substrate of mild cognitive impairment , 2000, Neurobiology of Aging.

[39]  W. Markesbery,et al.  Survival of hippocampal and cortical neurons in a mixture of MEM+ and B27-supplemented neurobasal medium. , 2000, Free Radical Biology & Medicine.

[40]  W. Markesbery,et al.  Decreased base excision repair and increased helicase activity in Alzheimer's disease brain , 2000, Brain Research.

[41]  C. Frye,et al.  The neurosteroid, 3α-androstanediol, prevents inhibitory avoidance deficits and pyknotic cells in the granule layer of the dentate gyrus induced by adrenalectomy in rats , 2000, Brain Research.

[42]  J. Wegiel,et al.  Cerebellar atrophy in Alzheimer's disease—clinicopathological correlations , 1999, Brain Research.

[43]  W. Markesbery,et al.  Increased DNA Oxidation and Decreased Levels of Repair Products in Alzheimer's Disease Ventricular CSF , 1999, Journal of neurochemistry.

[44]  G. Gibson,et al.  Protein‐Bound Acrolein , 1999, Journal of neurochemistry.

[45]  C Xie,et al.  Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease , 1998, Neurology.

[46]  W. Markesbery,et al.  Increased Nuclear DNA Oxidation in the Brain in Alzheimer's Disease , 1998, Journal of neurochemistry.

[47]  W. Markesbery,et al.  Four-Hydroxynonenal, a Product of Lipid Peroxidation, is Increased in the Brain in Alzheimer’s Disease , 1998, Neurobiology of Aging.

[48]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[49]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[50]  T. Montine,et al.  Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. , 1997, The American journal of pathology.

[51]  R J Mark,et al.  Amyloid β-Peptide Impairs Glucose Transport in Hippocampal and Cortical Neurons: Involvement of Membrane Lipid Peroxidation , 1997, The Journal of Neuroscience.

[52]  B. Yu,et al.  4-Hydroxyhexenal Is a Potent Inducer of the Mitochondrial Permeability Transition (*) , 1996, The Journal of Biological Chemistry.

[53]  B. Yu,et al.  Inhibition of adenine nucleotide translocator by lipid peroxidation products. , 1995, Free radical biology & medicine.

[54]  Patrizia Mecocci,et al.  Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease , 1994, Annals of neurology.

[55]  F. V. van Kuijk,et al.  4-Hydroxyhexenal: a lipid peroxidation product derived from oxidized docosahexaenoic acid. , 1990, Biochimica et biophysica acta.

[56]  H. Braak,et al.  Alzheimer's disease: amyloid plaques in the cerebellum , 1989, Journal of the Neurological Sciences.

[57]  Henry A. Erlich,et al.  Analysis of enzymatically amplified β-globin and HLA-DQα DNA with allele-specific oligonucleotide probes , 1986, Nature.

[58]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[59]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[60]  M. Ingvar,et al.  The Influence of Bicuculline‐Induced Seizures on Free Fatty Acid Concentrations in Cerebral Cortex, Hippocampus, and Cerebellum , 1982, Journal of neurochemistry.

[61]  D. Allan Butterfield,et al.  Acrolein inhibits NADH-linked mitochondrial enzyme activity: Implications for Alzheimer's disease , 2009, Neurotoxicity Research.

[62]  W. Markesbery,et al.  Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. , 2007, Neurobiology of disease.

[63]  Charles D. Smith,et al.  Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.

[64]  K. Jung,et al.  Induction of endothelial iNOS by 4-hydroxyhexenal through NF-kappaB activation. , 2004, Free radical biology & medicine.

[65]  H. Chung,et al.  NF-kappaB activation mechanism of 4-hydroxyhexenal via NIK/IKK and p38 MAPK pathway. , 2004, FEBS letters.

[66]  S. Hirai,et al.  Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated byβ protein immunostain , 2004, Acta Neuropathologica.

[67]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[68]  E. Coligan.  Current protocols in immunology , 1991 .

[69]  H A Erlich,et al.  Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. , 1986, Nature.